Skip to main content
. Author manuscript; available in PMC: 2020 Dec 3.
Published in final edited form as: Liver Int. 2018 Feb;38(Suppl 1):7–13. doi: 10.1111/liv.13673

FIGURE 4.

FIGURE 4

C-EDGE COSTAR: efficacy of 12 weeks GRZ/EBV in GT 1, 4 or 6 patients receiving OST.23 DAAs results in high rates of SVR in people who inject drugs; 92% (184/201) in the immediate treatment group. In this study, 0%-3% of patients discontinued treatment because of adverse events. Among 18 patients with post-treatment viral recurrence through 24-week follow-up, 6 had probable reinfection